Curasight has reported its Q2/21 quarterly report. The financial P&L is not of great importance for an upcoming biotech company, but it is encouraging to see excellent cost discipline. The company has made progress at lower costs than we expected and is now, on the back of encouraging preclinical and clinical data, ready to further accelerate its plans for uTREAT (therapy) and uTRACE (diagnostic). Our valuation range is unchanged at DKK 30-80 per share.

Länk till analysen